Database Update: Pharmaceutical Drug Import to Russia (November 2017)
Over the first 11 months of 2017, Russia imported 557.8 bln RUB worth of pharmaceutical drugs (free circulation prices, VAT included), which is a 4.3% increase against the same period of 2016. The import of ready-made drugs has increased by 9.2% and amounts to 472.2 bln RUB. The import of in-bulk products account for 85.6 bln RUB, with the decline by 16.4%.
November mostly followed the trend of 2017. The import of ready-made drugs has increased by 11.6% in monetary terms over the year, and amounts to 52.1 bln RUB. In November, the import of in-bulk drugs amounted to 7.5 bln RUB, which is a 26% decline against the same period of 2016.
Between January and November 2017, Russia imported 1.84 bln RUB worth of ready-made drugs, or 33.3 bln minimum dosage units (MDU). While the long-term growth rate of import products is positive if calculated in units (+5.5%), it is negative if calculated in MDU (-2 %). Despite the decline in imports in monetary terms, the in-bulk imports have been growing steadily (+7.3% if calculated in MDU). The total volume of the import of ready-made and in-bulk pharmaceuticals reached 37.5 bln MDUs, while the total growth rate is still negative (-1.1%).
Over the 11 months, Saudi Arabia has had the biggest increase in the import of ready-made drugs. The import has grown by more than 9 times, with Suprax (Astellas) being the most imported drug. Thailand has had the biggest increase in the import of in-bulk drugs, with the import having grown by nearly 11 times. The most imported drug was Utrogestan (Besins Healthcare), which is packaged by Ultrolek in Russia.
Read more about pharmaceutical drug import to Russia (October performance) here: http://rncph.com/news/17_11_2017
Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2016 – November 2017)